
Merck & Co., Inc. company profile
$143.16−0.90%Close 17 Nov 2026 · Market value $354.8B
About Merck & Co., Inc.
Merck & Co., Inc. (Merck) is a global health care company that develops and markets prescription medicines, including biologic therapies, vaccines and animal health products. It operates two reportable segments. The Pharmaceutical segment offers human health therapeutic and preventive agents, generally sold by prescription, and pediatric, adolescent and adult vaccines, selling primarily to drug wholesalers and retailers, hospitals, government agencies, managed health care providers, physicians and distributors. The Animal Health segment offers veterinary pharmaceutical and vaccine products, health management solutions and digitally connected identification and traceability products for livestock and companion animals, selling to veterinarians, distributors, animal producers, farmers and pet owners. The Company's products are sold in markets across the world.
A summary of the business section of the company's latest annual report, filed 24 Feb 2026.
Company facts
| Ticker | MRK · NYSE |
|---|
| Sector | Pharmaceuticals |
|---|
| Industry | Pharmaceuticals |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 310158 |
|---|
| Latest annual report | 10-K, filed 24 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Robert M. Davis | Chairman, CEO & President · Director | 1.2M · < 1% | Shares withheld for tax, 29 Apr 2026 |
|---|
| Sanat Chattopadhyay | Exe V-P & Pres. MMD | 573K · < 1% | Option exercise, 29 Apr 2026 |
|---|
| Dean Li | Executive VP & President, MRL | 405K · < 1% | Option exercise, 29 Apr 2026 |
|---|
| Caroline Litchfield | EVP & CFO | 378K · < 1% | Shares withheld for tax, 29 Apr 2026 |
|---|
| Jennifer Zachary | EVP, General Counsel | 125K · < 1% | Option exercise, 12 Aug 2026 |
|---|
| Inge G. Thulin | Director | 28.4K · < 1% | Open-market purchase, 6 Feb 2025 |
|---|
| Douglas M. Baker, Jr. | Director | 25.6K · < 1% | Open-market purchase, 5 Feb 2025 |
|---|
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | — | Option exercise, 12 Nov 2026 |
|---|
| Guindo Chirfi | EVP, Access, Policy & Comms | — | Open-market sale, 13 Aug 2026 |
|---|
| Maraldo David R. | EVP & Pres. MMD | — | Option exercise, 5 Aug 2026 |
|---|
| Williams David Michael | EVP,Chief Info&Digital Officer | — | Option exercise, 5 Aug 2026 |
|---|
| Smart Dalton E. III | SVP Fin. - Global Controller | — | Option exercise, 2 May 2026 |
|---|
| Larson Betty D | EVP, Chief HR Officer | — | Option exercise, 30 Apr 2026 |
|---|
| Oosthuizen Johannes Jacobus | EVP, Oncology & Int?l | — | Shares withheld for tax, 29 Apr 2026 |
|---|
| Romanelli Joseph | President, Human Health Int?l | — | Grant or award, 26 Jan 2026 |
|---|
| Downing Cristal N | Chief Comm. & Public Afrs Ofcr | — | Open-market sale, 10 Nov 2025 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
MRK in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.